

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

**THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19:  
A SYSTEMATIC REVIEW OF MECHANISMS AND EVIDENCE**

Stefanie Kalfas, MD<sup>1</sup>

Kumar Visvanathan, MBBS FRACP PhD<sup>2,3</sup>

Kim Chan, DSc PhD<sup>4</sup>

John Drago, MBBS FRACP PhD<sup>1,5\*</sup>

<sup>1</sup>Florey Institute of Neuroscience and Mental Health, University of Melbourne, VIC, Australia

<sup>2</sup>Department of infectious Diseases, St. Vincent’s Hospital, Melbourne, VIC, Australia

<sup>3</sup>Department of Medicine, Dentistry and Health Sciences, University of Melbourne, VIC, Australia

<sup>4</sup>Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, NSW, Australia

<sup>5</sup>Department of Neurology, St. Vincent’s Hospital, Melbourne, VIC , Australia

\*corresponding author: [john.drago@florey.edu.au](mailto:john.drago@florey.edu.au)

Word count (excluding abstract): 3,676

53 **ABSTRACT**

54 Introduction: Ivermectin is a commonly used antihelminthic agent with over 35 years of  
55 established safety data in humans. Recent data demonstrates antiviral activity in vitro  
56 against SARS-CoV-2, in addition to a range of viruses. In vitro and animal models also provide  
57 evidence of immunomodulatory action. These additional modes of action are supported by  
58 in silico modelling, which propose a number of viral and host targets that would mediate  
59 these effects.

60 Objectives: The aim of this study is to systematically review the published and preprint  
61 clinical literature and study results that assessed the potential role of ivermectin as a COVID-  
62 19 therapeutic and prophylactic agent.

63 Methods: We conducted a comprehensive review of PubMed, medRxiv, ClinicalTrials.gov,  
64 Global Coronavirus COVID-19 Clinical Trial Tracker, World Health Organization International  
65 Clinical Trials Registry Platform, EU Clinical Trials Register, ANZ clinical trials registry, and  
66 references from relevant articles.

67 Results: Search keywords- "COVID-19 (and synonyms) AND ivermectin"- generated 86  
68 articles on PubMed, 48 on medRxiv and 37 on clinicaltrials.gov at the time of writing. Twelve  
69 of these were listed as completed clinical trials and of these, 8 were included as investigators  
70 had released results. Positive mortality benefit, reduced time to clinical recovery, reduced  
71 incidence of disease progression and decreased duration of hospital admission were  
72 reported in patients across all stages of clinical severity.

73 Limitations: Due to the time-critical nature of the COVID-19 pandemic our review included  
74 preprint data, which must be interpreted with caution while it awaits peer review.

75

76 **INTRODUCTION- COVID-19**

77 The health and economic impact of COVID-19 is unparalleled. There has been no threat in  
78 recent times of the magnitude of COVID-19 to human survival and economic stability, with  
79 over 1,190,000 deaths reported globally to date and baseline economic forecasts of a 5.2 %  
80 contraction in global GDP in 2020.<sup>1,2</sup> The likelihood of death in an at-risk population is  
81 substantial, with an estimated infection fatality ratio ranging between 11.6% and 16.4% in  
82 men  $\geq 80$  years, and between 4.6% and 6.5% in women  $\geq 80$  years.<sup>3</sup> There is no validated  
83 vaccine for COVID-19 and there is currently no approved drug therapy that when given early  
84 in the disease course reduces morbidity or mortality. Treatments must therefore be  
85 established to mitigate the current global crisis. Furthermore, in order for these to be  
86 delivered in an egalitarian fashion, these must be affordable with scalable manufacturing  
87 potential to allow for delivery of therapy to be equitable and widespread. Repurposing of  
88 the anti-parasitic drug ivermectin to treat COVID-19 has become a point of scientific  
89 investigation following a study in Australia, which demonstrated its efficacy against SARS-  
90 CoV-2 in vitro.<sup>4</sup> As many countries around the world find themselves in the grips of  
91 progressively more ominous second and third epidemic waves, we present the current in  
92 vitro, in silico and in vivo data surrounding the potential role of ivermectin in treating COVID-  
93 19.

94

95 **IVERMECTIN- AN OVERVIEW**

96 Ivermectin is a broad spectrum anti-parasitic agent that was first semi-synthetically derived  
97 from a fermentation broth of the soil bacteria *Streptomyces avermitilis* in 1975 in Japan.<sup>5,6</sup> It  
98 belongs to the avermectin family and is the most widely used anti-parasitic in this class of  
99 drugs.<sup>6</sup> It is listed as an essential medication by WHO and has been called a “wonder drug”.<sup>7</sup>  
100 In 2015, William Campbell and Satoshi Ōmura were awarded a joint Nobel Prize in Medicine  
101 for their discovery and development of ivermectin.

102

103 For over 35 years ivermectin has been successfully used to treat various parasitic infections  
104 in humans and animals. Hundreds of millions of courses of ivermectin are delivered every  
105 year through mass drug administration campaigns as well as on an individual basis for the  
106 eradication of helminthic and arthropodal infections. Ivermectin binds to glutamate gated  
107 chloride channels in invertebrate nerve and muscle cell membranes, resulting in membrane  
108 hyperpolarisation which then leads to paralysis and death. These chloride channels are  
109 specific to protostome invertebrate phyla.<sup>8</sup> While they are closely related to mammalian  
110 glycine receptors, ivermectin has a low affinity for mammalian ligand-gated chloride  
111 channels. In addition, ivermectin does not readily cross an intact blood brain barrier.<sup>7</sup>  
112 Mutations in the *ABCB1* transporter gene known to occur in some animal species have been  
113 reported in humans but are predicted to be rare and should be readily recognized clinically  
114 as acute central nervous system (CNS) toxicity.<sup>9</sup> These signs and symptoms can include  
115 tremor, myoclonus, ataxia, drooling, bradypnoea, anorexia, somnolence, mydriasis,  
116 salivation and paralysis.

117

118 Ivermectin is currently licensed for oral and topical use in humans, and oral, topical and  
119 parenteral use in animals, with standard dosing used typically between 150-400  $\mu\text{g}/\text{kg}$ .<sup>7</sup>  
120 There are several case reports of ivermectin being successfully used subcutaneously to treat  
121 patients with disseminated strongyloidiasis who fail oral therapy.<sup>10</sup>

122

123 Ivermectin has a well characterized wide safety margin, with several phase 1 studies  
124 demonstrating its safety even at 5-10 times its usual dose of 150-200  $\mu\text{g}/\text{kg}$ , although there  
125 is limited data in pregnancy.<sup>7,11-15</sup> There are no absolute drug contraindications listed by the

126 manufacturer.<sup>16</sup> There have been rare reports of increased INR when ivermectin has been  
127 co-prescribed with warfarin.<sup>17</sup>

128

129 Side effects are usually mild and self-limited, and include headache, dizziness, skin irritation  
130 and nausea.<sup>17</sup> A cumulative incidence of one serious adverse event per million was found  
131 over the first 11 years of mass global ivermectin (trade name, Mectizan) administration.<sup>18</sup>

132

133

#### 134 **IVERMECTIN- ANTIVIRAL PROPERTIES**

135 In addition to its anti-helminthic effects, ivermectin has also been shown to have antiviral  
136 activity in vitro against numerous RNA and DNA viruses, including simian virus 40,  
137 pseudorabies virus, human Immune-deficiency virus, dengue virus, West Nile virus,  
138 Venezuelan equine encephalitis, influenza virus and yellow fever virus.<sup>19-25</sup> This broad-  
139 spectrum antiviral activity is thought to be a result of the fact that ivermectin inhibits viral  
140 protein transport mediated through the host importin  $\alpha/\beta$  heterodimer (IMP- $\alpha/\beta$ ).<sup>24</sup> Viral  
141 protein translocation into the host nucleus through IMP  $\alpha/\beta$  is known to be a crucial aspect  
142 of robust infection for many viruses.<sup>26-28</sup>

143

144 The virological efficacy of ivermectin against dengue infection has been demonstrated in a  
145 phase III clinical trial using 400  $\mu\text{g}/\text{kg}$ , although no clinical efficacy was demonstrated in this  
146 study.<sup>29</sup> This may be due to timing and dosing regimen of ivermectin.

147

148 An in vitro study recently demonstrated that ivermectin is active against SARS-CoV2, with  
149 concentrations of 5  $\mu\text{M}$  resulting in a 99.8% reduction of cell-associated SARS-CoV-2 RNA in  
150 48 hours.<sup>4</sup> While these drug concentrations are unlikely to be achieved in humans through  
151 currently approved oral dosing regimens, this does not discount the possibility of efficacy in  
152 vivo for many reasons. First, viral loads typically deployed for in vitro transfection  
153 experiments are very high and may not be representative of the clinical scenario. Second, a  
154 simple monolayer of the African green monkey kidney cells (Vero-hSLAM cells) with virus  
155 introduced in the supernatant does not replicate the complex/dynamic human tissue  
156 structure. Third, Vero-hSLAM cells may not be representative of the human model of  
157 infection as these cells are not respiratory cells and do not have ACE-2 receptors through  
158 which SARS-CoV-2 mediates cell entry.<sup>30</sup> Fourth, viral replication efficiency may vary in  
159 different cell types. Indeed, Vero-hSLAM cells is a cell line favoured specifically for viral  
160 replication. Fifth, synergistic effects inherent in the immunomodulatory and anti-  
161 inflammatory properties of ivermectin may also result in lower concentrations required to  
162 treat COVID-19. Finally, concentration limitations may potentially be overcome through  
163 novel routes of administration and dosing regimens.

164

165

#### 166 **IVERMECTIN- ANTI-INFLAMMATORY AND IMMUNOMODULATORY PROPERTIES**

167 Ivermectin and avermectin have been demonstrated to have anti-inflammatory and  
168 immunomodulatory actions in several in vitro and animal models, and is licensed for topical  
169 use in humans for the treatment of inflammatory lesions in rosacea.<sup>31</sup>

170

171 A recent proteomic analysis showed that ivermectin decreases levels of proteins associated  
172 with SARS-CoV-2 in an in vitro culture system.<sup>32</sup> An in vitro model of lipopolysaccharide (LPS)  
173 induced inflammation demonstrated that avermectin, from which ivermectin is derived,  
174 significantly impairs pro-inflammatory cytokine secretion (interleukin-1  $\beta$  and tumour  
175 necrosis factor- $\alpha$ ) by 30% and doubles secretion of the immunoregulatory cytokine  
176 interleukin (IL)-10. This effect is thought to be mediated through inhibition of nuclear

177 translocation of nuclear transcription factor  $\kappa$ -B (NF- $\kappa$ B), and phosphorylation of mitogen  
178 activated protein (MAP) kinases.<sup>33</sup> Mice treated with ivermectin demonstrated improved  
179 survival rates with a reduction in tumour necrosis factor- $\alpha$  and IL-1, IL-6 compared to  
180 controls following a lethal dose of LPS.<sup>34</sup> The dose used in this study was approximately  
181 equivalent to about 18 mg in humans.<sup>35</sup> In a mouse model of allergic asthma,  
182 bronchoalveolar lavage fluid in oral ivermectin treated mice (2 mg/kg) demonstrated a  
183 significantly reduced number of immune cells and production of pro-inflammatory cytokines  
184 and antibodies compared to controls.<sup>36</sup> A suppression of mucous secretion by goblet cells  
185 was also observed. Immunomodulatory and anti-inflammatory effects have also been  
186 observed in a murine model of atopic dermatitis, where ivermectin was shown to improve  
187 allergic skin inflammation.<sup>37</sup> Ivermectin was shown to directly inhibit antigen-specific and  
188 non-specific-CD4+ and CD8+ T cell proliferation and effector functions (IL-4, interferon- $\gamma$  and  
189 granzyme B production), whilst having no effect on dendritic cell migration and maturation.

190

191

### 192 **IVERMECTIN- IN SILICO MODELLING**

193 In silico models have raised the possibility that ivermectin may have several mechanisms of  
194 action against COVID-19 in addition to the established inhibition of IMP  $\alpha/\beta$ . It is possible  
195 that ivermectin may be able to prevent cell entry of SARS-CoV-2 through blockade of a high  
196 affinity docking site on the human angiotensin converting enzyme 2 (ACE-2) receptor that  
197 has been identified through two independent computational modelling studies.<sup>38,39</sup> The  
198 positioning of this identified binding site could theoretically interfere with the SARS-CoV-2  
199 spike glycoprotein binding, and thus reduce viral entry into cells. Using a novel computation  
200 method to analyse kinetically active residues, Perisic showed homology between the binding  
201 site of ivermectin with its known target in parasites (glycine receptor  $\alpha$  3) and proteins on  
202 the surface of SARS-CoV-2.<sup>40</sup> Furthermore, two computational biology and molecular  
203 docking studies identified ivermectin as a potentially effective inhibitor of the RNA-  
204 dependent RNA polymerase of SARS-CoV-2.<sup>41,42</sup>

205

206

### 207 **METHODS**

208 We conducted a comprehensive review of PubMed, medRxiv, ClinicalTrials.gov, Global  
209 Coronavirus COVID-19 Clinical Trial Tracker, World Health Organization International Clinical  
210 Trials Registry Platform, EU Clinical Trials Register, ANZ clinical trials registry, and references  
211 from relevant articles. Search keywords were “COVID-19 (and synonyms) AND ivermectin”.  
212 SK conducted the systematic review and selected articles. Decision regarding inclusion was  
213 then verified by JD and KC. Studies were included if they had released results at the time of  
214 writing. Studies were excluded if they had not released results, or if they had been retracted.  
215 Studies were not excluded based on site of study, time of follow-up or comparator arm.  
216 Study participants were limited to PCR confirmed COVID-19 patients and close contacts  
217 (healthcare workers and household contacts) of PCR confirmed COVID-19 patients. The  
218 intervention was ivermectin as either a monotherapy or combination therapy for COVID-19  
219 or prophylaxis for COVID-19, irrespective of dose and timing of administration. Outcome  
220 measures in the treatment trials included all-cause mortality and time to clinical recovery, in  
221 addition secondary measures that included time to viral clearance and disease progression.  
222 The primary outcome measure in the prophylaxis trials was development of symptoms  
223 consistent with COVID-19 and/or development of PCR confirmed COVID-19.

224

225

226

### 227 **RESULTS**

228 Our trials database search using the keywords “COVID-19” and synonyms AND “ivermectin”  
229 revealed 86 articles on PubMed, 48 on medRxiv and 37 on clinicaltrials.gov at the time of  
230 writing. Of these, 12 were completed clinical studies that examined the effect of ivermectin  
231 as a combination or single therapy for COVID-19 treatment and prophylaxis. Eight of these  
232 had released results at the time of writing this review and met inclusion criteria. Of these  
233 studies, four are randomised controlled trials, one is a prospective cohort study, one is a  
234 matched case control study, one is a retrospective analysis, and one is a pilot study. Five of  
235 these studies were disease treatment trials, and three were prophylaxis trials. We expand  
236 upon these published and preprint results below, which are summarised in Table 1 and  
237 Table 2.

238  
239

#### 240 **DISCUSSION- DATA FROM CLINICAL STUDIES**

241 A multicentre retrospective analysis, known as the ICON study, reported an overall mortality  
242 benefit ( $p=0.03$ ) in moderate-severe COVID-19 patients ( $n=173$ ) who were given at least one  
243 dose of oral ivermectin in addition to standard therapy, compared to matched controls  
244 ( $n=107$ ).<sup>43</sup> Two hundred and eight consecutive COVID-19 patients recruited across four  
245 hospitals in Florida were included in the study undertaken between March 15 and May 11,  
246 and divided into a treatment arm and a control arm. Standard approved dosing of 200  $\mu\text{g}/\text{kg}$   
247 was used, administered either as a single dose or followed by a second dose on day 7 at the  
248 discretion of the physician. Thirteen of the 173 patients who received ivermectin were given  
249 a second dose. Most patients in both groups were also prescribed hydroxychloroquine,  
250 azithromycin or both, with a higher use of both drugs noted in the control group before the  
251 secondary matched analysis. A statistically significant association between reduced mortality  
252 and ivermectin use was observed ( $p= 0.03$ ). This was even more pronounced in the subset of  
253 severe patients, with a mortality of 80.7% in controls vs 38.8 in the ivermectin group ( $p=$   
254  $0.001$ ). This association remained significant following multivariate analysis to adjust for  
255 comorbidities and differences between groups, and in a propensity score-matched cohort  
256 ( $p=0.045$  for total group;  $p= 0.002$  in severe subset). The absolute risk reduction was 11.7%.  
257 These results compare with the observed absolute risk reduction of dexamethasone use in  
258 severe patients of 12.1% seen in the RECOVERY trial, which was pivotal in introducing  
259 corticosteroids as standard of care in severe and critical COVID-19 patients in many  
260 countries.<sup>44,45</sup> Despite a significant difference in overall mortality, and mortality in severely  
261 unwell COVID-19 patients, the ICON study was not powered to detect a mortality difference  
262 in moderately unwell patients, nor a reduction in duration of hospital stay or the rate of  
263 successful extubation. As a retrospective analysis it is also limited by potential unmeasured  
264 confounding factors, however the ivermectin group tended to have a greater proportion of  
265 patients with known COVID-19 risk factors.

266

267 A reduced time to hospital discharge was demonstrated in a pilot prospective preprint study  
268 of 16 hospitalised COVID-19 patients administered one dose of 200  $\mu\text{g}/\text{kg}$  ivermectin in  
269 addition to standard therapy, compared to 71 matched controls receiving standard therapy  
270 alone ( $7.62 \pm 2.75$  versus  $13.22 \pm 0.90$  days,  $p=0.00005$ ).<sup>46</sup> Standard therapy was defined as  
271 hydroxychloroquine and azithromycin in this study. A signal for reduced mortality was also  
272 observed in the ivermectin group, however the study was not powered to address this  
273 endpoint.

274

275 A preprint observational analysis in medRxiv has reported on the mortality benefit of  
276 ivermectin combination therapy, known as the IDEA protocol, in COVID-19 patients ( $n=167$ )  
277 when compared to overall COVID-19 mortality in the region across the same time period  
278 ( $p=0.0475$ ).<sup>47</sup> The IDEA protocol consists of three permutations of an ivermectin

279 combination treatment regime based on severity of COVID-19 upon commencement. This  
280 includes incrementally increasing doses of ivermectin and either aspirin or enoxaparin  
281 depending on severity of illness, as well as dexamethasone for moderate-severe hospitalised  
282 patients. Ivermectin doses of 300 µg/kg, 450 µg/ kg and 600 µg/ kg were prescribed to mild  
283 (n=135), moderate (n=12) and severe (n=22) cases respectively on days 0 and 7. A total of  
284 167 patients were included in this study, with an average age of 55.7 years. Primary  
285 outcomes were progression of disease and 30 day mortality. There was a 0% rate of  
286 symptom progression within 7 days of follow-up in the mild patient group (n=135). No  
287 patients in this subgroup required admission to hospital and all made a full recovery. In the  
288 moderate to severe group (n=32), only one patient died after both 30 days and 2 months of  
289 follow up. Aside from this patient, disease progression did not occur in any of the remaining  
290 31 moderate-severe patients after commencement of the IDEA protocol, and all proceeded  
291 to recover. This is in contrast to the interim report from the World Health Organisation  
292 (WHO) SOLIDARITY trial, which failed to show a reduction in disease progression with  
293 remdesivir, lopinavir, interferon β1 or hydroxychloroquine.<sup>48</sup> The overall mortality reported  
294 with the IDEA protocol was 0.59%. This compares to an overall mortality in the region of  
295 approximately 2.1% (p=0.045). The mortality rate in moderate-severe patients (n=32)  
296 receiving the IDEA protocol was 3.1%, as compared to a mortality rate of 25% in patients  
297 admitted to the same hospital over the same period who did not receive the IDEA protocol  
298 (n=12). This study is limited by the absence of a concurrent control arm with a matched  
299 number of moderate to severe patients. The overall 28 day mortality in a large randomised  
300 placebo controlled trial of remdesivir for COVID-19 was reported as 11.4% in the remdesivir  
301 group, compared to 15.2% in the control group.<sup>49</sup> In the subset of moderate to severe  
302 patients (ordinal score 5-7 at baseline) randomised to receive remdesivir, 12.2% died by day  
303 28. The classification of moderate to severe disease between the IDEA and Remdesivir trials  
304 was comparable according to the study methods.

305  
306 Doxycycline is a broad-spectrum antimicrobial with anti-inflammatory activities that has  
307 recently been shown to inhibit SARS-CoV-2 cell entry and replication in vitro, leading to trials  
308 that examine the synergistic effects of doxycycline and ivermectin.<sup>50,51</sup> There are now two  
309 randomised controlled trials comparing ivermectin and doxycycline combination therapy  
310 with standard therapy that have published results on medRxiv and ClinicalTrials.gov  
311 (NCT04523831).<sup>52,53</sup> The largest of these included 363 mild to moderate COVID-19 patients  
312 and tested a treatment regimen of a single dose of 6-12 mg ivermectin on day 0, with a 5  
313 day course of 100mg doxycycline twice daily (NCT04523831).<sup>53</sup> 183 of the participants were  
314 randomised to receive ivermectin combination therapy plus standard care, while the  
315 remaining 180 were randomised to receive standard care. Results published on  
316 ClinicalTrials.gov indicate a higher rate of early clinical improvement within 7 days in the  
317 treatment group (60.7%) compared to control group (44.4%) (p=0.03) in addition to a lower  
318 rate of clinical deterioration in the treatment group (8.7%) vs control (17.8%) (p=0.013). This  
319 was mirrored in improved rates of viral clearance in the treatment group, where 7.7% of the  
320 treatment group vs 20% of controls were still returning a positive SARS-CoV-2 PCR 12 day  
321 after initial diagnosis. A mortality signal was also demonstrated, with zero deaths in the  
322 treatment group, compared to 3 deaths in the control group (1.6%). This is in contrast to  
323 corticosteroids, which, when used early are associated with possible harm.<sup>44,45</sup> We await  
324 final analysis of these results in both preprint and peer-reviewed publication.

325  
326 A randomised control trial in medRxiv studied the effect of ivermectin and doxycycline  
327 combination therapy on severe and critical COVID-19 patients in addition to mild to  
328 moderate cases.<sup>52</sup> Seventy patients were randomised to the treatment arm, which consisted  
329 of 2-3 days of 200 µg/kg of ivermectin and 100 mg doxycycline twice daily for 5-10 days, in

330 addition to standard therapy. Forty eight patients in the treatment group were classified as  
331 mild-moderate, 11 as severe and 11 critical. This compared to 48 mild-moderate patients in  
332 the control arm and 22 severe patients. No critically ill patients were randomised to the  
333 control arm due to ethical considerations. A mortality benefit was demonstrated in the  
334 severe subset of patients, with a mortality rate of 0% in the treatment group compared to  
335 27.27% in the control group ( $p=0.052$ ). No patients died in the mild-moderate subsets of  
336 either group. The mortality rate in the critical group was 18.2%, and although there was no  
337 direct comparator group in this trial, this was lower than the mortality rate of the severe  
338 control group. Published mortality rates in COVID-19 patients admitted to ICU range  
339 between approximately 25.7%- 59.5%.<sup>54</sup> The WHO SOLIDARITY trial, in which 11,266 adult  
340 patients with COVID-19 were randomised to one of 4 or local standard of care reported an  
341 mortality rate of 49% amongst critically patients who were already intubated at time of  
342 randomisation.<sup>48</sup> A reduced median time to recovery was also demonstrated in both mild-  
343 moderate (6.34±2.4 days vs 13.66±6.4 days) and severe groups (20.27±7.8 vs 24.25±9.5  
344 days) compared to controls, although this only reached statistical significance in the mild-  
345 moderate group ( $p<0.01$ ), possibly due to small sample size of the severe group. This  
346 translates to a reduced time to recovery of 7.32 days in the mild-moderate treatment group  
347 and 3.98 days in the severe treatment group. The overall median time to recovery in the  
348 treatment group was 10.61±5.3 days vs 17.9±6.8 days ( $p<0.01$ ). Remdesivir has been  
349 reported to reduce median time to recovery by 5 days ( $p<0.001$ ).<sup>55</sup> This has been conflicted  
350 by interim reports from the SOLIDARITY trial, which did not find a significant reduction in  
351 hospital admission.<sup>48</sup> Furthermore, the SOLIDARITY trial has reported no definite mortality  
352 benefit of remdesivir (RR=0.95, CI 0.81-1.11; 301 deaths in 2743 remdesivir group, 303  
353 deaths in the 2708 control group), even following a subgroup analysis for severity of illness.

354  
355 Preprint results indicating that ivermectin may have a role in COVID-19 prophylaxis have  
356 recently been released on ClinicalTrials.gov (NCT04425850, NCT04422561).<sup>53</sup> These are  
357 summarised in Table 2. The IVERCAR study enrolled 229 healthcare workers in Argentina and  
358 divided participants into two groups, with the treatment group receiving ivermectin buccal  
359 drops and carrageenan nasal spray in addition to personal protective equipment (PPE), and  
360 the control group using PPE alone (NCT04425850). After 28 days of follow-up, no  
361 participants in the treatment group ( $n=131$ ) had tested positive to COVID-19 compared to 11  
362 participants in the control group ( $n=98$ ), ( $p < 0.0001$ ).

363  
364 These results were mirrored in a randomised controlled trial in Egypt, in which 304  
365 participants who had household contacts with confirmed COVID-19 were randomised to  
366 receive ivermectin (200-400 µg/kg on day 1 and day 3) or placebo (NCT04422561). Within  
367 the 14-day follow-up period, 7.4% of the treatment group had developed symptoms  
368 consistent with COVID-19, compared to 58.4% of the placebo group. PCR results had not  
369 been released at the time of writing this review, however even a reduction in symptomatic  
370 COVID-19 carries important individual health implications. These studies are in contrast to  
371 less encouraging or conflicting results from HCQ prophylaxis studies.<sup>56-58</sup>

372  
373 Consistent with other prophylaxis reports, a recently released preprint matched case control  
374 study on medRxiv that analysed various medications used experimentally as COVID-19  
375 prophylaxis, reported a 73% reduction of COVID-19 in healthcare workers following two  
376 doses of ivermectin (OR, 0.27; 95% CI 0.15-0.51).<sup>59</sup> The ivermectin prophylaxis regimen used  
377 in this study consisted of two doses of 300 µg/kg of ivermectin separated by 72 hours.

378  
379  
380

381 **FUTURE DIRECTIONS**

382 Evidence is mounting which suggests that ivermectin may be an important drug in the fight  
383 against COVID-19. In the midst of a global pandemic the importance of preprint studies has  
384 come to the fore; however, we still await the outcome of rigorous peer review. Attributing  
385 therapeutic benefit to ivermectin use alone will be challenging, as combination therapies  
386 were commonly deployed. Interestingly, the apparent benefits of ivermectin or ivermectin  
387 combination therapy against COVID-19 appear to potentially be relevant to all stages of  
388 illness, from prophylaxis to treatment of critically ill patients. This may be explained by the  
389 multi-pronged effects of ivermectin, which range from direct viral inhibition to  
390 immunomodulation to mitigation of cell access, as demonstrated by in vitro, in silico and  
391 animal studies. Further immunological work needs to be undertaken to determine the  
392 specific mechanism of action of ivermectin with respect to its anti-inflammatory effects in  
393 COVID-19. Ivermectin is widely available, inexpensive, easy to administer and has a wide  
394 safety margin. The potential benefits of ivermectin may be enhanced by non-parenteral drug  
395 delivery. Three studies have recently published safety data in animal models of inhaled and  
396 intranasal ivermectin, reporting that these routes are safe in their respective models.<sup>60-62</sup>  
397 Further research in dosing, routes of administration, synergistic therapies and drug  
398 interactions will help inform the safest and most efficacious approach.

399  
400

401 **REFERENCES**

- 402 1. World Health Organization Coronavirus disease 2019 (COVID-19) Weekly  
403 epidemiological update 24 August, 2020. 2020.  
404 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)  
405 [reports](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports) (accessed August 29 2020).
- 406 2. The World Bank. The Global Economic Outlook During the COVID-19  
407 Pandemic: A Changed World. . 2020.  
408 [https://www.worldbank.org/en/news/feature/2020/06/08/the-global-economic-](https://www.worldbank.org/en/news/feature/2020/06/08/the-global-economic-outlook-during-the-covid-19-pandemic-a-changed-world)  
409 [outlook-during-the-covid-19-pandemic-a-changed-world](https://www.worldbank.org/en/news/feature/2020/06/08/the-global-economic-outlook-during-the-covid-19-pandemic-a-changed-world) (accessed August 31  
410 2020).
- 411 3. Pastor-Barriuso R, Perez-Gomez B, Hernan MA, et al. SARS-CoV-2 infection  
412 fatality risk in a nationwide seroepidemiological study. *medRxiv* 2020:  
413 2020.08.06.20169722.
- 414 4. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug  
415 ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res* 2020; **178**:  
416 104787.
- 417 5. Campbell WC, Burg RW, Fisher MH, Dybas RA. The Discovery of Ivermectin  
418 and Other Avermectins. In: Magee PS, Kohn GK, Menn JJ, eds. Pesticide synthesis  
419 through rational approaches. Washington, DC: American Chemical Society; 1984: 5–  
420 20.
- 421 6. Fisher MH, Mrozik H. The chemistry and pharmacology of avermectins. *Annu*  
422 *Rev Pharmacol Toxicol* 1992; **32**: 537–53.
- 423 7. Crump A, Ōmura S. Ivermectin, 'wonder drug' from Japan: the human use  
424 perspective. *Proc Jpn Acad Ser B Phys Biol Sci* 2011; **87**(2): 13–28.
- 425 8. Wolstenholme AJ. Glutamate-gated chloride channels. *J Biol Chem* 2012;  
426 **287**(48): 40232–8.
- 427 9. Baudou E, Lespine A, Durrieu G, et al. Serious Ivermectin Toxicity and Human  
428 ABCB1 Nonsense Mutations. *N Engl J Med* 2020; **383**(8): 787–9.
- 429 10. Marty FM, Lowry CM, Rodriguez M, et al. Treatment of human disseminated  
430 strongyloidiasis with a parenteral veterinary formulation of ivermectin. *Clin Infect Dis*  
431 2005; **41**(1): e5–8.
- 432 11. Geary TG. Ivermectin 20 years on: maturation of a wonder drug. *Trends*  
433 *Parasitol* 2005; **21**(11): 530–2.
- 434 12. Kircik LH, Del Rosso JQ, Layton AM, Schaubert J. Over 25 Years of Clinical  
435 Experience With Ivermectin: An Overview of Safety for an Increasing Number of  
436 Indications. *J Drugs Dermatol* 2016; **15**(3): 325–32.
- 437 13. Omura S. Ivermectin: 25 years and still going strong. *Int J Antimicrob Agents*  
438 2008; **31**(2): 91–8.
- 439 14. Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and  
440 pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. *J*  
441 *Clin Pharmacol* 2002; **42**(10): 1122–33.
- 442 15. Nicolas P, Maia MF, Bassat Q, et al. Safety of oral ivermectin during  
443 pregnancy: a systematic review and meta-analysis. *Lancet Glob Health* 2020; **8**(1):  
444 e92–e100.
- 445 16. Merck Sharp & Dohme BV. Stromectol (Ivermectin): Product Information.  
446 Netherlands: Merck, Sharp & Dohme Corp.; 2018.

- 447 17. Gilbert BW, Slechta J. A Case of Ivermectin-Induced Warfarin Toxicity: First  
448 Published Report. *Hosp Pharm* 2018; **53**(6): 393–4.
- 449 18. Omura S, Crump A. Ivermectin: panacea for resource-poor communities?  
450 *Trends Parasitol* 2014; **30**(9): 445–55.
- 451 19. Götz V, Magar L, Dornfeld D, et al. Influenza A viruses escape from MxA  
452 restriction at the expense of efficient nuclear vRNP import. *Sci Rep* 2016; **6**: 23138.
- 453 20. Lundberg L, Pinkham C, Baer A, et al. Nuclear import and export inhibitors  
454 alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine  
455 Encephalitis Virus replication. *Antiviral Res* 2013; **100**(3): 662–72.
- 456 21. Lv C, Liu W, Wang B, et al. Ivermectin inhibits DNA polymerase UL42 of  
457 pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro  
458 and vivo. *Antiviral Res* 2018; **159**: 55–62.
- 459 22. Mastrangelo E, Pezzullo M, De Burghgraeve T, et al. Ivermectin is a potent  
460 inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new  
461 prospects for an old drug. *J Antimicrob Chemother* 2012; **67**(8): 1884–94.
- 462 23. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a  
463 specific inhibitor of importin  $\alpha/\beta$ -mediated nuclear import able to inhibit replication  
464 of HIV-1 and dengue virus. *Biochem J* 2012; **443**(3): 851–6.
- 465 24. Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral  
466 ivermectin targets the host nuclear transport importin  $\alpha/\beta$ 1 heterodimer. *Antiviral  
467 Res* 2020; **177**: 104760.
- 468 25. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral  
469 effects to COVID-19 complementary regimen. *J Antibiot (Tokyo)* 2020; **73**(9): 593–  
470 602.
- 471 26. Jans DA, Martin AJ, Wagstaff KM. Inhibitors of nuclear transport. *Curr Opin  
472 Cell Biol* 2019; **58**: 50–60.
- 473 27. Fulcher AJ, Jans DA. Regulation of nucleocytoplasmic trafficking of viral  
474 proteins: an integral role in pathogenesis? *Biochim Biophys Acta* 2011; **1813**(12):  
475 2176–90.
- 476 28. Caly L, Wagstaff KM, Jans DA. Nuclear trafficking of proteins from RNA  
477 viruses: Potential target for antivirals? *Antiviral Research* 2012; **95**(3): 202–6.
- 478 29. Yamasmith E, A-hamad Saleh-arong F, Avirutnan P, et al. Efficacy and Safety  
479 of Ivermectin against Dengue Infection: A Phase III, Randomized, Double-blind,  
480 Placebo-controlled Trial. The 34th Annual Meeting The Royal College of Physicians  
481 of Thailand Pattaya, Chonburi, Thailand The Royal College of Physicians of Thailand;  
482 2018.
- 483 30. Jans DA, Wagstaff KM. Ivermectin as a Broad-Spectrum Host-Directed  
484 Antiviral: The Real Deal? *Cells* 2020; **9**(9).
- 485 31. Steinhoff M, Vocanson M, Voegel JJ, Hacini-Rachinel F, Schäfer G. Topical  
486 Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence  
487 on the Complementary Use of Anti-Inflammatory Rosacea Treatments. *Adv Ther*  
488 2016; **33**(9): 1481–501.
- 489 32. Li N, Zhao L, Zhan X. Quantitative proteomics reveals a broad-spectrum  
490 antiviral property of ivermectin, benefiting for COVID-19 treatment. *J Cell Physiol*  
491 2020.

- 492 33. Ci X, Li H, Yu Q, et al. Ivermectin exerts anti-inflammatory effect by  
493 downregulating the nuclear transcription factor kappa-B and mitogen-activated  
494 protein kinase activation pathway. *Fundam Clin Pharmacol* 2009; **23**(4): 449–55.
- 495 34. Zhang X, Song Y, Ci X, et al. Ivermectin inhibits LPS-induced production of  
496 inflammatory cytokines and improves LPS-induced survival in mice. *Inflamm Res*  
497 2008; **57**(11): 524–9.
- 498 35. DiNicolantonio JJ, Barroso J, McCarty M. Ivermectin may be a clinically useful  
499 anti-inflammatory agent for late-stage COVID-19. *Open Heart* 2020; **7**(2).
- 500 36. Yan S, Ci X, Chen N, et al. Anti-inflammatory effects of ivermectin in mouse  
501 model of allergic asthma. *Inflamm Res* 2011; **60**(6): 589–96.
- 502 37. Ventre E, Rozières A, Lenief V, et al. Topical ivermectin improves allergic skin  
503 inflammation. *Allergy* 2017; **72**(8): 1212–21.
- 504 38. Kalhor H, Sadeghi S, Abolhasani H, Kalhor R, Rahimi H. Repurposing of the  
505 approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human  
506 ACE2 interaction through virtual screening approaches. *J Biomol Struct Dyn* 2020: 1–  
507 16.
- 508 39. Lehrer S, Rheinstein PH. Ivermectin Docks to the SARS-CoV-2 Spike  
509 Receptor-binding Domain Attached to ACE2. *In Vivo* 2020; **34**(5): 3023–6.
- 510 40. Perišić O. Recognition of Potential COVID-19 Drug Treatments through the  
511 Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of  
512 Kinetically Active Residues. *Biomolecules* 2020; **10**(9).
- 513 41. Dagher Janabi AH. Effective Anti-SARS-CoV-2 RNA Dependent RNA  
514 Polymerase Drugs Based on Docking Methods: The Case of Milbemycin, Ivermectin,  
515 and Baloxavir Marboxil. *Avicenna J Med Biotechnol* 2020; **12**(4): 246–50.
- 516 42. Parvez MSA, Karim MA, Hasan M, et al. Prediction of potential inhibitors for  
517 RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug  
518 repurposing and molecular docking approach. *Int J Biol Macromol* 2020; **163**: 1787–  
519 97.
- 520 43. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin  
521 Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease  
522 2019: The ICON Study. *Chest* 2020.
- 523 44. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients  
524 with Covid-19 – Preliminary Report. *N Engl J Med* 2020.
- 525 45. Matthay MA, Thompson BT. Dexamethasone in hospitalised patients with  
526 COVID-19: addressing uncertainties. *The Lancet Respiratory Medicine*.
- 527 46. Gorial FI, Mashhadani S, Sayaly HM, et al. Effectiveness of Ivermectin as add-  
528 on Therapy in COVID-19 Management (Pilot Trial). *medRxiv* 2020:  
529 2020.07.07.20145979.
- 530 47. Carvallo HE, Hirsch RR, Farinella ME. Safety and Efficacy of the combined use  
531 of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19. *medRxiv*  
532 2020: 2020.09.10.20191619.
- 533 48. Pan H, Peto R, Karim QA, et al. Repurposed antiviral drugs for COVID-19 –  
534 interim WHO SOLIDARITY trial results. *medRxiv* 2020: 2020.10.15.20209817.
- 535 49. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of  
536 Covid-19 — Final Report. *New England Journal of Medicine* 2020; **383**(19): 1813–26.
- 537 50. Gendrot M, Andreani J, Jardot P, et al. In Vitro Antiviral Activity of  
538 Doxycycline against SARS-CoV-2. *Molecules* 2020; **25**(21).

- 539 51. Cazalis J, Bodet C, Gagnon G, Grenier D. Doxycycline reduces  
540 lipopolysaccharide–induced inflammatory mediator secretion in macrophage and ex  
541 vivo human whole blood models. *J Periodontol* 2008; **79**(9): 1762–8.
- 542 52. Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulmir AS.  
543 Controlled randomized clinical trial on using ivermectin with Doxycycline for treating  
544 COVID–19 patients in Baghdad, Iraq. *medRxiv* 2020: 2020.10.26.20219345.
- 545 53. ClinicalTrials.gov. Search Results for: ivermectin | Completed Studies |  
546 Studies With Results | Covid19. 2020.  
547 <https://clinicaltrials.gov/ct2/results?term=ivermectin&cond=Covid19&recrs=e&age>  
548 [v=&gndr=&type=&rslt=With&Search=Apply](https://clinicaltrials.gov/ct2/results?term=ivermectin&cond=Covid19&recrs=e&age) (accessed November 5 2020).
- 549 54. Quah P, Li A, Phua J. Mortality rates of patients with COVID–19 in the  
550 intensive care unit: a systematic review of the emerging literature. *Crit Care* 2020;  
551 **24**(1): 285.
- 552 55. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of  
553 Covid–19 — Preliminary Report. *N Engl J Med* 2020.
- 554 56. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of  
555 Hydroxychloroquine as Postexposure Prophylaxis for Covid–19. *N Engl J Med* 2020;  
556 **383**(6): 517–25.
- 557 57. Bhattacharya R, Chowdhury S, Mukherjee R, et al. Pre exposure  
558 hydroxychloroquine prophylaxis for covid–19 in healthcare workers: a retrospective  
559 cohort. *medRxiv* 2020: 2020.06.09.20116806.
- 560 58. Rajasingham R, Bangdiwala AS, Nicol MR, et al. Hydroxychloroquine as pre–  
561 exposure prophylaxis for COVID–19 in healthcare workers: a randomized trial.  
562 *medRxiv* 2020: 2020.09.18.20197327.
- 563 59. Behera P, Patro BK, Singh AK, et al. Role of ivermectin in the prevention of  
564 COVID–19 infection among healthcare workers in India: A matched case–control  
565 study. *medRxiv* 2020: 2020.10.29.20222661.
- 566 60. Ji L, Cen J, Lin S, et al. Study on the subacute inhalation toxicity of ivermectin  
567 in TC rats. *Chinese Journal of Comparative Medicine* 2016; **26**(3): 70–4.
- 568 61. Errecalde J, Lifschitz A, Vecchioli G, et al. Ivermectin repurposing for COVID–  
569 19 therapy: Safety and pharmacokinetic assessment of a novel nasal spray  
570 formulation in a pig model. *bioRxiv* 2020: 2020.10.23.352831.
- 571 62. Chaccour C, Abizanda G, Irigoyen–Barrio Á, et al. Nebulized ivermectin for  
572 COVID–19 and other respiratory diseases, a proof of concept, dose–ranging study in  
573 rats. *Scientific Reports* 2020; **10**(1): 17073.  
574  
575

576 **ACKNOWLEDGEMENTS**

577 Thank you to Dr. Salvatore Fiorenza for valuable discussions and assistance with manuscript  
578 proof reading.

579

580

581 **CONFLICTS OF INTEREST**

582 The authors declare no relevant conflicts of interest.

Study reference	Study design	Study intervention	Total number of participants	Mortality rate (treatment group vs. comparator)	Disease progression or viral clearance (treatment group vs. comparator)	Duration of hospital admission or time to recovery (treatment group vs. comparator)
Rajter et al. 2020 <sup>42</sup>	Multicentre retrospective analysis	1-2 doses of 200 µg/kg IVM + standard therapy vs. standard therapy	280 hospitalised patients (IVM)= 173 (control)= 107	Overall study results 15% vs. 25.2% (p=0.03)  Severe disease 38.8% vs. 80.7% (p=0.001)	No difference in successful rate of extubation	No significant difference
Gorial et al. 2020 <sup>45</sup>	Matched case-control	1 dose of 200 µg/kg IVM + standard therapy vs. standard therapy	87 hospitalised patients (IVM) = 16 (control)= 71	0% vs. 2.8% (p value not given)	Time to viral clearance: 7 days (95% CI 6-11) vs. 12 days (95% CI 10-15) (p<0.001)	7.62 ±2.75 vs. 13.22 ±0.90 days (p=0.00005)
Carvalho et al. 2020 <sup>46</sup>	Prospective single cohort study (simultaneous untreated controls)	IDEA protocol: Mild cases: IVM 300 µg/kg + aspirin Moderate cases: IVM 450 µg/kg + aspirin + dexamethasone Severe cases: 600 µg/kg IVM + enoxaparin + dexamethasone	167 mild-severe patients (mild) = 135 (moderate) = 12 (severe) = 22	Overall: 0.59%  Mild cases: 0%  Mod-severe cases: 3.1% Mortality of patients not on IDEA protocol at same hospital over duration of study: 25%	Disease progression: Mild cases: 0% 7 day symptom progression 0% required hospitalisation Moderate-severe cases: 1 patient (3.1%) had disease progression	Not reported

<p>NCT04523831 <sup>50</sup></p>	<p>Double blind randomised controlled trial</p>	<p>6-12 mg IVM + 5 days DOXY + standard therapy vs. standard therapy</p>	<p>363 mild - moderate (treatment) = 183 (control) = 180</p>	<p>0 % vs. 1.6% (p value not reported)</p>	<p>Clinical deterioration: 8.7% vs 17.8% (p=0.013)  Viral clearance within 12 days: 92.3% vs. 80 % (p value not reported)</p>	<p>Clinical recovery within 7 days:  60.7% vs. 44.4% (p=0.03)</p>
<p>Hashim et al. 2020 <sup>49</sup></p>	<p>Randomised controlled trial</p>	<p>2-3 days of 200 µg/kg IVM + 5-10 days DOXY + standard therapy vs. standard therapy</p>	<p>140 mild-critical patients (treatment) = 70 (48= mild-mod, 11= severe, 11= critical) (control) = 70 (48= mild-mod, 22=severe)</p>	<p>Mild=mod: 0% vs 0% Severe: 0% vs. 27.27 % (p=0.052)</p>	<p>Disease progression in severe cases: 9% vs. 31.81 % (p=0.15)</p>	<p>Time to recovery: 10.61±5.3 days vs. 17.9±6.8 days (p&lt;0.01)</p>

**Table 1.** Summary of key therapeutic ivermectin trials. (IVM ivermectin. DOXY doxycycline). Ivermectin was administered orally in all trials. “Standard therapy” differed between trials and is defined as the standard therapy administered in the region/hospital at the given period of the trial.

Study reference	Study design	Study intervention	Total number of participants	Incidence of COVID-19 infection (treatment vs. control)
NCT04425850 <sup>50</sup>	Prospective placebo controlled trial	1 drop IVM buccal drops (6mg/ml) + 5 sprays carrageenan nasal spray (0.17mg/spray) both repeated 5 times per day + PPE vs. PPE only	229 Healthcare workers (treatment) = 131 (control) = 98	0% vs. 11.22% Positive SARS-CoV2 PCR within 28 days (p<0.0001)
NCT04422561 <sup>50</sup>	Randomised controlled trial	IVM 200-400 µg/kg oral on day 1 and day 3 vs. no intervention	304 household contacts of confirmed COVID-19 case	7.4% vs. 58.4% symptomatic within 14 days (p value not reported)
Behera et al. 2020 <sup>56</sup>	Matched case-control study	Two doses IVM 300 µg/kg oral + PPE vs. PPE only	186 matched case-control pairs of Healthcare workers 77 controls took IVM 38 cases took IVM	IVM use associated with a 73% reduction. OR, 0.27 (95% CI 0.15-0.51)

**Table 2.** Summary of key COVID-19 prophylaxis ivermectin trials. (IVM ivermectin. PEE personal protective equipment)